A growing number of biotechnology companies, both in the West and in Asia, are specializing in gene therapies and other regenerative treatments boosted by the approval of the first genetic therapy agent (tisagenlecleusel) by the FDA in 2017. Between 2015 and 2019, the number of industry-sponsored genetic therapy trials more than quadrupled (CAGR + 43%), with the Asia-Pacific region being involved in about 40% of all trials (ex-Japan). Since 2001, over 300 sites in Asia-Pacific have been involved in 335 different genetic therapy trials.
Novotech 點出遠端智慧臨床試驗在 2024 年加速全球生物科技臨床試驗方面的潛力和挑戰
香港，2023 年 11 月 26 日-- Novotech,作為以亞太區為中心，營運能力涉及全球多個國家和地區的業內專業生物科技受託研究機構 (CRO)，報告